Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cannabis-derived products antagonize platinum drugs by altered cellular transport

T. Buchtova, L. Beresova, K. Chroma, T. Pluhacek, T. Beres, D. Kaczorova, P. Tarkowski, J. Bartek, M. Mistrik

. 2023 ; 163 (-) : 114801. [pub] 20230501

Language English Country France

Document type Journal Article

Cannabinoids, a class of compounds derived from Cannabis sativa L., have recently become more widely accessible for public consumption in the form of diverse cannabis products, in parallel with weakening the measures that so far restricted their availability. The US Food and Drug Administration has approved several cannabis-derived drugs for management of various diseases as well as chemotherapy-induced nausea and vomiting. Besides the attenuation of adverse effects of chemotherapy, numerous reports about cannabinoid-mediated anticancer effects further motivate cancer patients to support their therapy with such products. Here we present a set of preclinical data with human cell culture models, suggesting that cannabidiol and cannabis extracts may effectively counteract the anticancer effects of the clinically widely used standard-of-care platinum-based drugs. We show that even low concentrations of cannabinoids reduced the toxicity of cisplatin, oxaliplatin, and carboplatin, an effect which was accompanied by decreased platinum adduct formation and a set of commonly used molecular markers. Mechanistically, our results excluded the possibility that the observed enhanced survival of cancer cells was mediated transcriptionally. Instead, trace metal analyses strongly indicate an inhibitory impact of cannabinoids on intracellular platinum accumulation, thereby implicating changes in cellular transport and/or retention of these drugs as the likely cause of the observed biological effects. Our study raises the possibility that the desirable effect of counteracting adverse effects of chemotherapy might, at least for some cannabinoids, reflect impaired cellular availability, and consequently attenuation of the anticancer effects of platinum drugs. DATA AVAILABILITY: All data supporting the conclusions are available in the article and supplementary files. Raw data are available upon request from the corresponding author.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010907
003      
CZ-PrNML
005      
20250506100749.0
007      
ta
008      
230718e20230501fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2023.114801 $2 doi
035    __
$a (PubMed)37137184
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Buchtova, Tereza $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Olomouc, Czech Republic
245    10
$a Cannabis-derived products antagonize platinum drugs by altered cellular transport / $c T. Buchtova, L. Beresova, K. Chroma, T. Pluhacek, T. Beres, D. Kaczorova, P. Tarkowski, J. Bartek, M. Mistrik
520    9_
$a Cannabinoids, a class of compounds derived from Cannabis sativa L., have recently become more widely accessible for public consumption in the form of diverse cannabis products, in parallel with weakening the measures that so far restricted their availability. The US Food and Drug Administration has approved several cannabis-derived drugs for management of various diseases as well as chemotherapy-induced nausea and vomiting. Besides the attenuation of adverse effects of chemotherapy, numerous reports about cannabinoid-mediated anticancer effects further motivate cancer patients to support their therapy with such products. Here we present a set of preclinical data with human cell culture models, suggesting that cannabidiol and cannabis extracts may effectively counteract the anticancer effects of the clinically widely used standard-of-care platinum-based drugs. We show that even low concentrations of cannabinoids reduced the toxicity of cisplatin, oxaliplatin, and carboplatin, an effect which was accompanied by decreased platinum adduct formation and a set of commonly used molecular markers. Mechanistically, our results excluded the possibility that the observed enhanced survival of cancer cells was mediated transcriptionally. Instead, trace metal analyses strongly indicate an inhibitory impact of cannabinoids on intracellular platinum accumulation, thereby implicating changes in cellular transport and/or retention of these drugs as the likely cause of the observed biological effects. Our study raises the possibility that the desirable effect of counteracting adverse effects of chemotherapy might, at least for some cannabinoids, reflect impaired cellular availability, and consequently attenuation of the anticancer effects of platinum drugs. DATA AVAILABILITY: All data supporting the conclusions are available in the article and supplementary files. Raw data are available upon request from the corresponding author.
650    _2
$a lidé $7 D006801
650    12
$a Cannabis $7 D002188
650    _2
$a léčivé přípravky $7 D004364
650    _2
$a platina $7 D010984
650    12
$a kanabinoidy $x terapeutické užití $7 D002186
650    12
$a kanabidiol $x farmakologie $x terapeutické užití $7 D002185
650    12
$a halucinogeny $7 D006213
650    _2
$a agonisté kanabinoidních receptorů $7 D063386
650    _2
$a analgetika $7 D000700
655    _2
$a časopisecké články $7 D016428
700    1_
$a Béresová, Lucie $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Olomouc, Czech Republic $7 xx0329564
700    1_
$a Chroma, Katarina $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Olomouc, Czech Republic
700    1_
$a Pluhacek, Tomas $u Department of Analytical Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 12, 771 46 Olomouc, Czech Republic
700    1_
$a Beres, Tibor $u Czech Advanced Technology and Research Institute, Palacký University, Olomouc, Czech Republic
700    1_
$a Kaczorova, Dominika $u Czech Advanced Technology and Research Institute, Palacký University, Olomouc, Czech Republic; Centre of the Region Haná for Biotechnological and Agricultural Research, Department of Genetic Resources for Vegetables, Medicinal and Special Plants, Crop Research Institute, Olomouc, Czech Republic
700    1_
$a Tarkowski, Petr $u Czech Advanced Technology and Research Institute, Palacký University, Olomouc, Czech Republic; Centre of the Region Haná for Biotechnological and Agricultural Research, Department of Genetic Resources for Vegetables, Medicinal and Special Plants, Crop Research Institute, Olomouc, Czech Republic
700    1_
$a Bártek, Jiří, $d 1953- $u Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark; Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, 171 77 Stockholm, Sweden $7 xx0046271
700    1_
$a Mistrik, Martin $u Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University, Olomouc, Czech Republic. Electronic address: martin.mistrik@upol.cz
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 163 (20230501), s. 114801
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37137184 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20250506100748 $b ABA008
999    __
$a ok $b bmc $g 1963367 $s 1197172
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 163 $c - $d 114801 $e 20230501 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...